Swedish Orphan Biovitrum, Pfizer sales and marketing update

Swedish Orphan returned co-promotion rights in the Nordic region to Pfizer for hemophilia A drug ReFacto AF moroctocog alfa and hemophilia B drug BeneFIX. Swedish Orphan will receive $47.5 million for the return of the rights and will remain eligible for royalties on Pfizer's global sales of both products. For the first nine months of 2011, Swedish Orphan recorded SEK542 million ($81.7 million) in ReFacto AF revenue, which includes SEK374 million ($56.4 million) from manufacturing, SEK95 million ($14.3 million) from royalties and SEK73 million ($11 million) from co-promotion. Swedish Orphan will continue to supply the drug substance for ReFacto through 2020 under a separate agreement. The company will also continue to supply BeneFIX. Swedish Orphan does not break out revenue for BeneFIX.

Swedish Orphan said returning the rights will allow the company to focus on building its own presence in the hemophilia area. The original deal was between Biovitrum AB and Wyeth. Wyeth was acquired by Pfizer in 2009, and Biovitrum acquired Swedish Orphan International AB in 2009 and changed its name. BeneFIX is a recombinant coagulation Factor IX (rFIX) and ReFacto AF is a recombinant Factor VIII ( rFVIII). ...